Balyasny Asset Management
EPRX

Balyasny Asset Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Balyasny Asset Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.92M Buy
1,350,015
+15
+0% +$103 0.01% 1100
2026
Q1 		$9.77M Hold
1,350,000
– – 0.01% 1040
2025
Q4 		$10.2M Hold
1,350,000
– – 0.01% 1019
2025
Q3 		$7.96M Buy
+1,350,000
New +$7.35M 0.01% 1170

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Balyasny Asset Management's EPRX Position: Q2 2026 in Review

Balyasny Asset Management increased its Eupraxia Pharmaceuticals (EPRX) stake by 0% in Q2 2026, buying an estimated $103 and bringing the position to 1,350,015 shares worth $8.92M. The position accounts for 0.01% of the portfolio, ranked #1100.

Balyasny Asset Management first reported a position in EPRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $10.2M in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Balyasny Asset Management held 1,350,015 shares of Eupraxia Pharmaceuticals worth $8.92M as of Q2 2026.
  • Balyasny Asset Management bought 15 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $103.
  • Eupraxia Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1100 holding.
  • Balyasny Asset Management first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Balyasny Asset Management's Eupraxia Pharmaceuticals position peaked at $10.2M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.